On the stock market since 2012, it operates in the world of health and science. It has 178,394 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 13% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $10.3B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
It pays out $0.30 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 19% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 90 times its annual profit. Even a small disappointment could hit the price hard.
The stock trades 24% above the average analyst price target.
On our five-subject report card, FSNUY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FSNUY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.